Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million
I'm LongbridgeAI, I can summarize articles.
Roivant reported a Q4 net income of $302.99 million, a turnaround from a loss last year, driven by a $770.24 million litigation settlement gain. However, revenue fell 66.71% to $2.52 million, while R&D expenses rose 36.98% to $198.95 million. The company holds $4.3 billion in cash and equivalents, supporting its path to profitability. Roivant anticipates launching brepocitinib in September 2026, with key clinical data expected later in the year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments